{ }
Very Negative
Negative
Neutral
Positive
Very Positive
2025-03-292025-03-292025-03-302025-03-302025-03-312025-03-312025-04-012025-04-012025-04-022025-04-022025-04-032025-04-032025-04-042025-04-041418203229814542444918917352324912012090906060303000
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-03-292025-03-292025-03-302025-03-302025-03-312025-03-312025-04-012025-04-012025-04-022025-04-022025-04-032025-04-032025-04-042025-04-0451696522302519104342685020101111712012090906060303000
Download SVG
Download PNG
Download CSV

ubs raises price target for hannover re shares to 267 euros

UBS AG has raised its price target for Hannover Re from EUR 238 to EUR 267 while maintaining a "Neutral" rating. The share price rose by 0.7% to EUR 257.10, indicating an upside potential of 3.85%. Hannover Re is set to release its Q3 2024 figures on November 11, 2024.
12:13 18.10.2024

gold prices expected to rise amid safe haven demand and rate cuts

Gold prices are expected to rise over the next 6-12 months, driven by declining interest rates and strong central bank purchases. Analysts predict prices could reach $2,900 per ounce by September 2025, supported by geopolitical tensions and economic uncertainty, despite potential slower rate cuts from the Federal Reserve.
12:06 18.10.2024

ubs rates pernod ricard neutral with target price of 138 euros

UBS has rated Pernod Ricard as 'Neutral' with a target price of 138 euros. The company leads in premium and prestige spirits and wines, with net sales primarily from international brands (61.8%), local brands (18.2%), craft spirits (7.3%), and strategic wines (3.6%). Geographically, sales are distributed across Europe (28.3%), America (28.8%), and other regions (42.9%), supported by 94 production sites worldwide.
11:58 18.10.2024

ubs upgrades sanofi to buy with target price of 110 euros

UBS has upgraded Sanofi to a 'Buy' rating with a target price of 110 euros, citing the neurodermatitis drug Dupixent as a key growth driver for the company in the third quarter. Analyst Carl Walton anticipates that growth will accelerate further in 2025.
11:57 18.10.2024

ubs upgrades sanofi to buy with target price of 110 euros

UBS has upgraded its rating for Sanofi to "Buy," setting a target price of 110 euros. Analyst Carl Walton highlighted that the neurodermatitis drug Dupixent is expected to drive growth for the company in the third quarter, with acceleration anticipated in 2025.
11:57 18.10.2024

manufacturing output remains stable despite pessimistic sentiment surveys

UBS economist Paul Donovan highlights a disconnect between sentiment surveys and actual economic performance, particularly in manufacturing. Despite frequent negative signals from surveys, real manufacturing output has remained stable, suggesting that pessimistic biases in sentiment do not reflect economic reality. This issue is more pronounced in Europe due to limited data releases and delays in reporting.
11:55 18.10.2024

misleading sentiment surveys distort perception of economic reality

Financial journalism often conflates sentiment with economic reality, leading to contradictory headlines about manufacturing output. Despite pessimistic sentiment surveys, actual manufacturing performance has remained stable, particularly in the US and Germany, where media emphasis on negative sentiment can distort perceptions of the economy. Investors should be cautious, as these surveys tend to reflect a pessimistic bias that does not align with the true economic situation.
11:44 18.10.2024

UBS shares reach new high amid positive market outlook and analysis

UBS shares reached a new high of 28.18 francs, currently priced at 30.27 euros, reflecting a 0.72% increase and an impressive 8.65% gain over the past month, showcasing strong investor confidence. In a recent analysis, UBS raised its price target for Nokia from EUR 3.55 to EUR 4.00 while maintaining a "Hold" rating, indicating cautious optimism about the company's prospects.
11:34 18.10.2024

UBS raises Nokia target price to four euros maintains neutral rating

UBS has increased its target price for Nokia from 3.55 to 4.00 euros while maintaining a "Neutral" rating. Analyst Francois-Xavier Bouvignies noted that the company's strong cost management offsets the challenges in the current market.
11:28 18.10.2024

UBS raises Nokia target price to four euros while maintaining neutral rating

UBS has increased its target price for Nokia from 3.55 to 4.00 euros while maintaining a "Neutral" rating. Analyst Francois-Xavier Bouvignies noted that the company's strong cost management helps offset challenges in the market.
11:28 18.10.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.